Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALIM Alimera Sciences	$5.54	$5.55	$2.61 ▼ $5.65	$290.24M	1.25	376,318 shs	N/A
AMPH Amphastar Pharmaceuticals	$23.08 -0.4%	$24.79	$22.64 ▼ $53.96	$1.09B	0.77	497,082 shs	1.27 million shs
ARDX Ardelyx	$3.69 +0.3%	$4.00	$3.21 ▼ $8.06	$882.87M	0.6	4.49 million shs	3.11 million shs
DYN Dyne Therapeutics	$9.57 -4.8%	$11.83	$6.36 ▼ $47.45	$1.09B	1.17	1.76 million shs	4.65 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALIM Alimera Sciences	0.00%	0.00%	0.00%	0.00%	-0.36%
AMPH Amphastar Pharmaceuticals	0.00%	-6.03%	-10.82%	-20.39%	-42.30%
ARDX Ardelyx	0.00%	+3.65%	-0.81%	-24.85%	-50.20%
DYN Dyne Therapeutics	0.00%	-7.27%	-19.04%	-8.51%	-72.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALIM Alimera Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	4.248 of 5 stars	3.1	2.0	0.0	3.7	1.4	4.2	1.3
ARDX Ardelyx	4.4395 of 5 stars	3.5	3.0	0.0	4.4	2.7	2.5	0.6
DYN Dyne Therapeutics	3.6287 of 5 stars	4.5	3.0	0.0	0.0	2.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALIM Alimera Sciences	0.00	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	40.09% Upside
ARDX Ardelyx	3.00	Buy	$10.89	195.09% Upside
DYN Dyne Therapeutics	3.00	Buy	$41.13	329.73% Upside

Current Analyst Ratings Breakdown

Latest ALIM, AMPH, ARDX, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/25/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2025	DYN Dyne Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/18/2025	DYN Dyne Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/18/2025	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$46.00 ➝ $32.00
6/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/11/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$37.00
6/2/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$60.00 ➝ $34.00
5/29/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$46.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALIM Alimera Sciences	$99.68M	2.91	N/A	N/A	$0.88 per share	6.30
AMPH Amphastar Pharmaceuticals	$731.97M	1.49	$5.01 per share	4.61	$15.23 per share	1.52
ARDX Ardelyx	$333.61M	2.65	N/A	N/A	$0.73 per share	5.05
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALIM Alimera Sciences	-$20.13M	-$1.57	N/A	26.38	N/A	-14.74%	-33.70%	-9.63%	N/A
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	8.36	7.02	6.01	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
ARDX Ardelyx	-$39.14M	-$0.22	N/A	11.90	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
DYN Dyne Therapeutics	-$317.42M	-$3.59	N/A	N/A	N/A	N/A	-52.83%	-48.84%	8/11/2025 (Estimated)

Latest ALIM, AMPH, ARDX, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	-$1.05	-$0.17	-$1.05	N/A	N/A
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALIM Alimera Sciences	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALIM Alimera Sciences	1.80	2.79	2.62
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
ARDX Ardelyx	1.04	4.12	3.81
DYN Dyne Therapeutics	N/A	20.35	20.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALIM Alimera Sciences	99.83%
AMPH Amphastar Pharmaceuticals	65.09%
ARDX Ardelyx	58.92%
DYN Dyne Therapeutics	96.68%

Insider Ownership

Company	Insider Ownership
ALIM Alimera Sciences	31.40%
AMPH Amphastar Pharmaceuticals	27.10%
ARDX Ardelyx	4.80%
DYN Dyne Therapeutics	20.77%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALIM Alimera Sciences	150	52.39 million	35.94 million	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.36 million	Optionable
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
DYN Dyne Therapeutics	100	113.67 million	90.06 million	Optionable

ALIM, AMPH, ARDX, and DYN Headlines

Recent News About These Companies

Dyne Therapeutics (NASDAQ:DYN) Gains Market Attention Russell 1000

June 27 at 8:58 PM | kalkinemedia.comK

Jones Trading initiates Dyne Therapeutics stock with buy rating

June 27 at 3:58 PM | investing.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

June 27 at 10:00 AM | prnewswire.com

Dyne Therapeutics (NASDAQ:DYN) Upgraded at Jones Trading

June 27 at 5:55 AM | marketbeat.com

Dyne Therapeutics (NASDAQ:DYN) Now Covered by Jones Trading

June 27 at 3:27 AM | americanbankingnews.com

Jones Trading Initiates Coverage of Dyne Therapeutics (DYN) with Buy Recommendation

June 26, 2025 | msn.com

Jones Trading Begins Coverage on Dyne Therapeutics (NASDAQ:DYN)

June 26, 2025 | marketbeat.com

Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $43.93 Average PT from Brokerages

June 26, 2025 | americanbankingnews.com

Dyne Therapeutics (NASDAQ:DYN) Shares Down 5.4% - Here's Why

June 25, 2025 | marketbeat.com

Sanford C. Bernstein Begins Coverage on Dyne Therapeutics (NASDAQ:DYN)

June 25, 2025 | americanbankingnews.com

Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101

June 24, 2025 | msn.com

Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at Sanford C. Bernstein

June 24, 2025 | marketbeat.com

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN

June 24, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Dyne Therapeutics, Inc. – DYN

June 23, 2025 | globenewswire.com

Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from Brokerages

June 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

June 22, 2025 | prnewswire.com

Parent Project Muscular Dystrophy Hosts 2025 Annual Conference in Las Vegas, Nevada

June 18, 2025 | finance.yahoo.com

Dyne adjusts regulatory timeline for DYNE-101 after FDA feedback

June 18, 2025 | thepharmaletter.comT

Dyne at ‘attractive entry point’ following pullback, says Chardan

June 18, 2025 | finance.yahoo.com

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade

June 18, 2025 | seekingalpha.com

Dyne Therapeutics' (DYN) "Buy" Rating Reiterated at Guggenheim

June 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALIM, AMPH, ARDX, and DYN Company Descriptions

Alimera Sciences NASDAQ:ALIM

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.08 -0.10 (-0.43%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$23.49 +0.41 (+1.78%)

As of 06/27/2025 06:05 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Ardelyx NASDAQ:ARDX

$3.69 +0.01 (+0.27%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.70 +0.02 (+0.41%)

As of 06/27/2025 07:23 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics NASDAQ:DYN

$9.57 -0.48 (-4.78%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.48 -0.09 (-0.94%)

As of 06/27/2025 07:58 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time